Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352092
Status:
COMPLETED
Last Update Posted:
2014-11-13
First Post:
2006-07-13
Brief Title:
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
Sponsor:
University of Cincinnati
Organization:
University of Cincinnati
Study Overview
Official Title:
A Pilot Study of Corticosteroid-Free Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical has a similar immune system
Detailed Description:
The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA - identical or in other words has a similar immune system The immune system is a defense system that the body uses to fight foreign substances that enter the body such as a transplanted kidney Two people with similar immune systems are less likely to fight off or reject an organ donated from one to the other HLA-identical kidney transplant recipients are less likely to need large amounts of immunosuppression because they are immunologically similar In this study you will be treated with the immunosuppressive medications Cellcept Rapamune and Prograf and after a rejection free period will remain on Cellcept alone This treatment regimen is currently being used at The University of Cincinnati for all HLA-identical living donor kidney transplant recipients This study is being conducted to determine if the protocol currently being used results in beneficial outcomes for HLA-identical kidney transplant recipients
Only recently have transplant centers considered avoiding steroid therapy prednisone in any transplant patient because steroids have been used successfully for so long but with many side effects The ability to stop steroids has occurred due to the availability of newer more effective immunosuppressive medications Stopping steroids has been tried in patients who are considered to be at both low and higher risk of kidney rejection Patients considered at risk for rejection may typically be left on steroids forever or no attempts to stop the steroids would be made until the patient is one year after transplant and has already received a lot of steroid therapy resulting in side effects This study will be conducted in patients that are low risk for rejection and can potentially benefit from steroid avoidance
Overall the concept of steroid avoidance in patients that are at low risk for rejection is now much more acceptable because newer more potent medications have recently become available to prevent acute rejection These newer medications include Prograf tacrolimus Cellcept mycophenolate mofetil and Rapamune sirolimus Currently most kidney transplant recipients receive medications consisting of tacrolimus or cyclosporine mycophenolate mofetil or azathioprine and steroids However recently the combination of Prograf tacrolimus and Rapamune sirolimus with steroid withdrawal 3 months after transplantation was studied in patients receiving liver liverkidney and kidneypancreas transplants This study showed a low rate of acute rejection with excellent patient and kidney survival
The addition of Cellcept to Prograf and Rapamune is thought to be a safe and effective alternative to the use of steroids in transplant patients Due to the low risk of rejection for HLA-identical kidney transplant recipients patients in this study will be slowly withdrawn from both Rapamune and Prograf over a rejection free period of time Withdrawal of these medications and avoidance of steroids could decrease the development of high blood pressure high cholesterol diabetes tremors and infection after transplant This study will determine if this medication regimen is safe effective and able to produce beneficial post transplant outcomes
Only recently have transplant centers considered avoiding steroid therapy prednisone in any transplant patient because steroids have been used successfully for so long but with many side effects The ability to stop steroids has occurred due to the availability of newer more effective immunosuppressive medications Stopping steroids has been tried in patients who are considered to be at both low and higher risk of kidney rejection Patients considered at risk for rejection may typically be left on steroids forever or no attempts to stop the steroids would be made until the patient is one year after transplant and has already received a lot of steroid therapy resulting in side effects This study will be conducted in patients that are low risk for rejection and can potentially benefit from steroid avoidance
Overall the concept of steroid avoidance in patients that are at low risk for rejection is now much more acceptable because newer more potent medications have recently become available to prevent acute rejection These newer medications include Prograf tacrolimus Cellcept mycophenolate mofetil and Rapamune sirolimus Currently most kidney transplant recipients receive medications consisting of tacrolimus or cyclosporine mycophenolate mofetil or azathioprine and steroids However recently the combination of Prograf tacrolimus and Rapamune sirolimus with steroid withdrawal 3 months after transplantation was studied in patients receiving liver liverkidney and kidneypancreas transplants This study showed a low rate of acute rejection with excellent patient and kidney survival
The addition of Cellcept to Prograf and Rapamune is thought to be a safe and effective alternative to the use of steroids in transplant patients Due to the low risk of rejection for HLA-identical kidney transplant recipients patients in this study will be slowly withdrawn from both Rapamune and Prograf over a rejection free period of time Withdrawal of these medications and avoidance of steroids could decrease the development of high blood pressure high cholesterol diabetes tremors and infection after transplant This study will determine if this medication regimen is safe effective and able to produce beneficial post transplant outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None